ArticleTrends in psychiatry and psychotherapy2025
Atomoxetine: toxicological aspects of a new treatment for attention deficit hyperactivity disorder in Brazil.
Article in Trends in psychiatry and psychotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAtomoxetine is widely used in the treatment of attention deficit hyperactivity disorder (ADHD), offering reduced risks of adverse motor effects and chemical dependence. However, its pharmacokinetic properties and toxicological risks require further exploration. This study aimed to predict the physicochemical profile, medicinal chemistry characteristics, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of atomoxetine using in silico web-based tools.
methodsPhysicochemical, medicinal chemistry, and pharmacokinetic parameters of atomoxetine were analyzed using predictive computational models. Emphasis was placed on properties that influence drug efficacy and safety, particularly in the context of ADHD treatment.
resultsIn silico analyses revealed that atomoxetine may carry potential risks of hepatotoxicity, cardiotoxicity, neurotoxicity, nephrotoxicity, respiratory system toxicity, skin toxicity, and carcinogenicity. These predicted toxicological effects highlight the importance of further investigation into atomoxetine's safety, especially across diverse patient populations and varying durations of treatment.
conclusionThe findings from this predictive study suggest that careful monitoring of atomoxetine use is warranted in clinical settings. Furthermore, additional controlled studies are needed to develop personalized dosing protocols that account for individual variability in metabolism and toxicity response, enabling a safer and more effective use of the drug.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.